NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-08-31
Reading ABBV? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Broken: Primary pillar broken — Increase adjusted diluted EPS to at least $14.28 in 2026: FY26 EPS guide $13.97 vs $14.28 target.
AbbVie grows revenue about 10% a year. It raised 2026 EPS guidance to about $14.28. The company invests $1.4 billion in manufacturing and expands its drug pipeline. It also increased its dividend by 5.5%.
Legal probes into China trials could hurt AbbVie's regulatory approvals. Acquired R&D expenses remain high, pressuring earnings. A small earnings miss in Q1 2026 shows risks to growth.
The price is about 9% above our fair value near $232. Analysts expect about 10% revenue growth. Our fair value is 12% below the Street median, reflecting some caution versus the Street's optimism.
Breaks if: Capital investments fall significantly below $1.78 billion in 2026
Invest in new manufacturing facilities and R&D capabilities to support growth in immunology, neuroscience, and oncology.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is characterized as a durable compounder with a focus on immunology. The current thesis state is intact, driven by robust earnings quality and strong recent financial performance.
The market appears to have priced in a justified valuation, though ABBV is seen as expensive compared to its peers. There is a slight expectations gap, indicating that investors may not expect significant surprises in the near term.
Fundamentals are likely to remain strong due to consistent growth in the immunology portfolio. However, the management's ability to manage expenses related to acquisitions may present mixed results in the near term.
The thesis hinges on ABBV's ability to raise guidance in upcoming quarters and the performance of key sector peers like LLY, JNJ, and MRK. Additionally, broader economic conditions, such as job growth, could impact sentiment and performance.
The most important moves since the prior daily snapshot.
Confidence changed from 'high' to 'medium'.
Mixed, the news cuts both ways. AbbVie advanced its immunology portfolio and pipeline. This supports growth expectations. However, the company cut its adjusted diluted EPS guidance. This threatens those same growth expectations.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 6 quarters. AbbVie announced a $1.4B investment in a pharmaceutical manufacturing campus in Durham, NC in 2026-Q1 and a $380M investment in API manufacturing facilities in North Chicago in 2025-Q4. These investments support growth in immunology, neuroscience, and oncology. The trajectory shows active capital deployment in manufacturing and R&D infrastructure.
“Announced $1.4 billion investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina.”
“Announced $380 million investment to build two new active pharmaceutical ingredient manufacturing facilities at North Chicago campus.”
“Broke ground on $195 million API facility in North Chicago and $70 million expansion at AbbVie Bioresearch Center in Worcester.”
Breaks if: Dividend per share falls below $1.64 or is cut
Breaks if: adjusted diluted EPS falls below $13.96 in 2026
Raise full-year adjusted diluted EPS guidance reflecting strong operational performance and pipeline progress.
Stated as a priority in 5 of last 6 quarters. AbbVie raised its adjusted diluted EPS guidance from $10.38-$10.58 in 2025-Q3 to $13.87-$14.07 in 2026-Q2, reflecting strong operational performance and pipeline progress. The trajectory shows consistent upward revisions in guidance aligned with reported results.
“Updates 2026 Adjusted Diluted EPS Guidance Range from $13.91 - $14.11 to $13.87 - $14.07 including acquisition impact.”
“Raises 2026 Adjusted Diluted EPS Guidance Range from $13.96 - $14.16 to $14.08 - $14.28.”
“Provides 2026 Adjusted Diluted EPS Guidance Range of $14.37 to $14.57.”
“Raises 2025 Adjusted Diluted EPS Guidance Range from $10.38 - $10.58 to $10.61 - $10.65.”
“Raises 2025 Adjusted Diluted EPS Guidance Range from $11.67 - $11.87 to $11.88 - $12.08.”
Breaks if: Significant regulatory setbacks or failure to advance key drugs like Skyrizi, Rinvoq, or Epkinly
Over the next 1 to 3 years, ABBV's growth trajectory in immunology and dividend consistency will be crucial, but valuation concerns and external economic factors must be monitored. Not investment advice.
